| Heading: |
Breast Cancer: Medical Treatments |
| Question ID: |
1819834 |
| UIN: |
65167 |
| House: |
Commons |
| Date tabled: |
2025-07-04 |
| Asking Member ID: |
5072 |
| Asking Member display name: |
Mr Andrew Snowden
|
| Asking Member handle: |
A_J_Snowden
|
| Asking Member Twitter reference: |
@A_J_Snowden
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the severity modifier introduced by NICE in 2022 on access to new treatments for secondary breast cancer. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-07-10 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The National Institute for Health and Care Excellence (NICE) is responsible for the methods and processes that it uses in the development of its recommendations. The severity modifier was introduced in January 2022 as part of a number of changes intended ... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |